Form 4: Tempest Therapeutics Director Receives Stock Option Grant

Director William Drake Richey was granted 25,000 stock options in Tempest Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Director William Drake Richey acquired 25,000 stock options in Tempest Therapeutics, Inc. (TPST).
• The options have an exercise price of $1.27 per share.
• The grant date for these options is June 4, 2026.
• The options are set to expire on June 4, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices rather than a signal of operational performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on the company's ability to achieve clinical or commercial milestones to increase share price above the $1.27 exercise price.

Future Outlook

The options vest over a three-year period, with one-third vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector, intended to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard industry practices for board-level equity compensation in small-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised.

Next Steps

• Vesting of the first tranche of options on June 4, 2027.

Key Dates

Keywords

Tempest Therapeutics, TPST, Form 4, Insider Trading, Stock Options, Director Compensation